People: Xenoport Inc (XNPT.O)

XNPT.O on Nasdaq

5.07USD
1:51pm EDT
Price Change (% chg)

$0.18 (+3.68%)
Prev Close
$4.89
Open
$4.88
Day's High
$5.10
Day's Low
$4.84
Volume
77,988
Avg. Vol
304,233
52-wk High
$7.20
52-wk Low
$3.14

Search Stocks

Summary

Name Age Since Current Position

Ronald Barrett

58 2001 Chief Executive Officer, Director

William Harris

54 2011 Chief Financial Officer, Senior Vice President - Finance

Vincent Angotti

45 2012 Chief Operating Officer, Executive Vice President

Gianna Bosko

43 2010 Chief Administrative Officer, Senior Vice President, General Counsel, Secretary

Gregory Bates

54 2012 Senior Vice President - Regulatory Affairs and Quality

Richard Kim

2014 Senior Vice President - Clinical Development and Medical Affairs, and Chief Medical Officer

David Savello

67 2010 Senior Vice President - Development Operations

John Freund

60 2008 Lead Independent Director

Ernest Mario

76 2012 Director

William Rieflin

54 2010 Director

Paul Berns

47 2005 Independent Director

Dennis Fenton

62 2009 Independent Director

Catherine Friedman

53 2007 Independent Director

Jeryl Hilleman

56 2005 Independent Director

Wendell Wierenga

66 2000 Independent Director

Jackie Cossmon

IR Contact Officer

Biographies

Name Description

Ronald Barrett

Dr. Ronald W. Barrett, Ph.D., is Chief Executive Officer, Director of XenoPort Inc. He served as our chief scientific officer from 1999 to 2001. Dr. Barrett has been a director since August 1999. From 1989 to 1999, he held various positions at Affymax Research Institute, a company employing combinatorial chemistry and high-throughput target screening for drug discovery, the most recent of which was senior vice president of research. Glaxo Wellcome plc, a pharmaceutical company, acquired Affymax Research Institute in 1995. Glaxo Wellcome subsequently merged with SmithKline Beecham plc, a pharmaceutical company, in 2000 to form GlaxoSmithKline plc, a pharmaceutical company. Prior to Affymax Research Institute, Dr. Barrett was a molecular pharmacologist in the Neuroscience Group at Abbott Laboratories, a healthcare company, from 1986 to 1989. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University.

William Harris

Mr. William G. Harris is Chief Financial Officer, Senior Vice President - Finance of XenoPort Inc., since November 2001. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., a biotechnology company engaged in the development of novel therapies for the treatment of cancer and autoimmune diseases, the most recent of which was senior vice president and chief financial officer. Corixa Corp., a developer of immunotherapeutic products, acquired Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, Inc., the most recent of which was director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration.

Vincent Angotti

Mr. Vincent J. Angotti is Chief Operating Officer, Executive Vice President of XenoPort, Inc. He was previously our senior vice president and chief commercialization officer from 2008 to 2012. From 2001 to 2008, he held several positions with Reliant Pharmaceuticals, Inc., a pharmaceutical company, the most recent of which was senior vice president of sales and marketing. GlaxoSmithKline acquired Reliant Pharmaceuticals in 2008. Prior to Reliant Pharmaceuticals, from 1991 to 2001, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, a pharmaceutical company, most recently as executive director, field operations. Mr. Angotti received a B.S. from Cornell University and an M.B.A. from Columbia University.

Gianna Bosko

Ms. Gianna M. Bosko is Chief Administrative Officer, Senior Vice President, General Counsel, Secretary of XenoPort Inc., since August 2010. She was previously our vice president, general counsel and secretary from 2007 to 2010, and senior corporate counsel from 2005 to 2007. From 2004 to 2005, Ms. Bosko was a legal consultant, providing general corporate and in-house legal consulting services for private and public companies, including XenoPort. From 1996 to 2004, she was an associate at Cooley LLP, a law firm, practicing general corporate and securities law, with an emphasis on securities transactions and mergers and acquisitions. Ms. Bosko received an A.B. from Stanford University and a J.D. from the University of Chicago Law School.

Gregory Bates

Mr. Gregory T. Bates, D.V.M., is Senior Vice President - Regulatory Affairs and Quality of XenoPort, Inc. since June 2012. He was previously our vice president of regulatory affairs from 2006 to June 2012. From 1998 to 2006, Dr. Bates held various positions at Pharmacyclics, Inc, a biopharmaceutical company, the most recent of which was senior director of regulatory affairs. Prior to Pharmacyclics, in 1998, Dr. Bates was director of regulatory affairs and quality at Otsuka America Pharmaceutical, Inc. From 1995 to 1998, he was manager of regulatory affairs at Genentech, Inc., a biotechnology company, and from 1990 to 1995, he was senior manager of agribusiness regulatory affairs at Syntex (USA), Inc., a pharmaceutical company. Dr. Bates received a B.A. from the University of California, Berkeley and a Doctor of Veterinary Medicine from the University of California, Davis.

Richard Kim

Dr. Richard Kim, M.D. is the Senior Vice President - Clinical Development and Medical Affairs, and Chief Medical Officer of XenoPort, Inc. Dr. Kim joined XenoPort in July 2013 as vice president of medical affairs, supporting XenoPort's launch of HORIZANT® (gabapentin enacarbil) Extended-Release Tablets. Dr. Kim has more than a decade of experience in both clinical development and medical affairs, most recently as vice president of clinical development and head of the multiple sclerosis therapeutic area at Elan Pharmaceuticals, Inc. In his previous position at Elan, Dr. Kim was joint program team leader for natalizumab (TYSABRI), which is approved globally for treatment of multiple sclerosis and approved for treatment of Crohn's Disease in the United States. Prior to Elan, he was the global medical affairs director for natalizumab at Biogen Idec Inc., during which he played an integral role in successfully re-launching TYSABRI in the United States, as well as its subsequent global launch. Prior to Biogen Idec, he was the medical director responsible for the cladribine Phase 3 program at EMD Serono, Inc. He began his industry career more than a decade ago at Purdue Pharma L.P., where he worked on the early development of buprenorphine transdermal patch (BUTRANS). Dr. Kim received his medical degree from Tulane University, completed his neurology residency training at Stanford University, and is a diplomat of the American Board of Psychiatry and Neurology.

David Savello

Dr. David R. Savello, Ph.D., is Senior Vice President - Development Operations of XenoPort Inc., since November 2010. He was previously our senior vice president of development from 2007 to November 2010. He was responsible for our regulatory affairs, quality and project management from 2005 to 2007. From 1999 to 2005, Dr. Savello was executive vice president and chief scientific officer for the Pharmaceutical Technology and Services Sector of Cardinal Health, Inc. Prior to joining Cardinal Health, from 1997 to 1999, he was senior vice president for drug development at Guilford Pharmaceuticals Inc. From 1985 to 1997, Dr. Savello held several positions at Glaxo and Glaxo Wellcome including both vice president of drug development and vice president of regulatory affairs and compliance. Prior to that, he held R&D management and executive management positions at Boehringer Ingelheim GmbH, and 3M Company. Dr. Savello received his B.S. degree from the Massachusetts College of Pharmacy and both an M.S. and a Ph.D. in pharmaceutics from the University of Maryland School of Pharmacy.

John Freund

Dr. John G. Freund, M.D., is Lead Independent Director of XenoPort, Inc., since July 2008. He has been a managing director of Skyline Ventures, a venture capital firm specializing in healthcare companies, since 1997. From 1995 to 1997, Dr. Freund was a managing director in the private equity group at Chancellor Capital Management, a private capital investment firm. AMVESCAP plc, an investment services company, acquired Chancellor Capital Management in 1998 and renamed the division INVESCO Private Capital. In 1995, he co-founded Intuitive Surgical, Inc., a medical device company. From 1988 to 1994, he held various positions at Acuson Corp., a maker of ultrasound equipment, most recently as executive vice president. Siemens Corp. acquired Acuson in 2000. Prior to Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners, a venture capital management firm, from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he was a co-founder of the Healthcare Group in the Corporate Finance Department. He received a B.A. from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School. Dr. Freund was a member of the boards of directors of The New Economy Fund, a U.S.-registered investment fund, from 2000 to 2009; Sirtris Pharmaceuticals, Inc., at the time a publicly-traded pharmaceutical company, from 2004 to 2008; Hansen Medical, Inc., a publicly-traded company specializing in medical robotics, from 2002 to 2010; and MAP Pharmaceuticals, Inc., a publicly-traded company developing inhalation-based pharmaceuticals, from 2004 to 2011. Dr. Freund is currently a member of the boards of directors of SMALLCAP World Fund, Fundamental Investors, Inc. and The Growth Fund of America, Inc., each of which are U.S.-registered investment funds, and MAKO Surgical Corp., a publicly-traded company that designs and sells an advanced robotic-arm solution, together with proprietary implants, for orthopedic knee procedures.

Ernest Mario

Dr. Ernest Mario, Ph.D., has been appointed as Director of XenoPort, Inc., with effect from June 15, 2012. Dr. Mario has served as chairman of the board and chief executive officer of Capnia, Inc., a privately-held pharmaceutical company, since August 2007. From April 2003 to August 2007, Dr. Mario served as chairman of the board and chief executive officer of Reliant Pharmaceuticals, Inc., a privately-held pharmaceutical company. From 1997 to 2001, Dr. Mario served as chairman and chief executive officer of ALZA Corporation, a pharmaceutical company, and as co-chairman and chief executive officer of ALZA from 1993 to 1997. From 1992 to 1993, Dr. Mario served as deputy chairman of Glaxo Holdings plc., a pharmaceutical company, and as chief executive from 1989 to 1993. Dr. Mario received a Ph.D. and an M.S. in physical sciences from the University of Rhode Island and a B.S. in pharmacy from Rutgers University. Dr. Mario previously served as a member of the boards of directors of IntraBiotics Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, from 2002 to 2007, and Pharmaceutical Product Development, Inc., a publicly-traded contract research organization, from 1993 to 2011. Dr. Mario is currently a member of the boards of directors of Boston Scientific Corporation, a publicly-traded medical device company; Celgene Corporation, a publicly-traded biopharmaceutical company; Maxygen, Inc., a publicly-traded biotechnology company, TONIX Pharmaceuticals Holding Corp, a publicly-traded specialty pharmaceutical company, and Vivus, Inc., a publicly-traded biopharmaceutical company.

William Rieflin

Mr. William J. Rieflin is Director of XenoPort, Inc., since September 2010. In September 2010, Mr. Rieflin was appointed chief executive officer and a member of the board of directors of NGM Biopharmaceuticals, Inc., a pharmaceutical company focused on metabolic diseases. Mr. Rieflin previously served as our president from 2004 to September 2010. From 1996 to 2004, he held various positions with Tularik Inc., a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression, the most recent of which was executive vice president, administration, chief financial officer, general counsel and secretary. Amgen Inc. acquired Tularik in 2004. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School. Mr. Rieflin is a member of the board of directors of Anacor Pharmaceuticals.

Paul Berns

Mr. Paul L. Berns is Independent Director of XenoPort, Inc., since November 2005. Mr. Berns currently is a self-employed consultant to the pharmaceutical industry. From March 2006 to August 2012, he served as president, chief executive officer and a member of the board of directors of Allos Therapeutics, Inc., a biopharmaceutical company, which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012. From 2002 to 2005, Mr. Berns was chief executive officer, president and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as vice president and general manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. He served as vice president, marketing of BASF Pharmaceuticals-Knoll, a pharmaceutical company, from 2000 to 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Berns received a B.S. from the University of Wisconsin. Mr. Berns is a member of the board of directors of Jazz Pharmaceuticals plc, a publicly-traded specialty pharmaceutical company, and Anacor Pharmaceuticals, Inc., a publicly-traded pharmaceutical company.

Dennis Fenton

Dr. Dennis M. Fenton, Ph.D., is Independent Director of XenoPort, Inc., since August 2009. From 1982 to 2008, Dr. Fenton held numerous positions, including executive roles in process development, manufacturing, sales and marketing and research and development, at Amgen, Inc., a biotechnology company. From 2000 to 2008, Dr. Fenton was executive vice president responsible for worldwide operations, manufacturing, process development and quality. From 1995 to 2000, Dr. Fenton was senior vice president of operations, and from 1992 to 1995, Dr. Fenton was senior vice president of sales, marketing and process development for Amgen. Dr. Fenton received a B.S. in biology from Manhattan College and a Ph.D. in microbiology from Rutgers University. Dr. Fenton is a member of the boards of directors of Dendreon Corporation, a publicly-traded biotechnology company, Hospira, Inc., a publicly-traded pharmaceutical company, and Kythera Biopharmaceuticals, Inc., a publicly-traded pharmaceutical company focused on the aesthetic medicine market. Dr. Fenton was a member of the board of directors of Genzyme Corporation, a publicly-traded biotechnology company, from 2010 to 2011.

Catherine Friedman

Ms. Catherine J. Friedman is Independent Director of XenoPort, Inc., since September 2007. Ms. Friedman has been an independent financial consultant serving private and public companies in the life sciences industry since 2006. Prior to that, Ms. Friedman held numerous positions over a 23-year investment banking career with Morgan Stanley & Co., an investment banking company, including managing director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. Ms. Friedman received a B.A. from Harvard College and an M.B.A. from the University of Virginia Darden School of Business. Ms. Friedman is a member of the boards of directors of EnteroMedics Inc., a publicly-traded medical device company focused on obesity management, and GSV Capital Corp., a publicly-traded investment fund.

Jeryl Hilleman

Ms. Jeryl L. Hilleman is Independent Director of XenoPort, Inc., since January 2005. From January 2008 to May 2012, she was chief financial officer of Amyris Biotechnologies, Inc., a company specializing in synthetic biology. Prior to joining Amyris in January 2008, she was executive vice president and chief financial officer of Symyx Technologies, Inc., a company specializing in high-throughput experimentation for the discovery of materials, from 1997 to June 2007. Prior to joining Symyx in 1997, Ms. Hilleman served as vice president finance and chief financial officer of two public biotechnology companies, Geron Corporation and Cytel Corporation, which merged with Epimmune Inc. in 1999. Ms. Hilleman received an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.

Wendell Wierenga

Dr. Wendell Wierenga, Ph.D., is Independent Director of XenoPort, Inc., since 2000. He is executive vice president, research and development at Santarus, Inc., a pharmaceutical company. Prior to joining Santarus in June 2011, he was executive vice president of research and development at Ambit Biosciences, Inc., a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors, since January 2007. Dr. Wierenga served as executive vice president of research and development at Neurocrine Biosciences, Inc., a biopharmaceutical company developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases, from 2003 to 2007. From 2000 to 2003, Dr. Wierenga was chief executive officer of Syrrx, Inc., a company focused on small-molecule drug compounds. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co., a pharmaceutical company. Pfizer Inc., a research-based pharmaceutical company, acquired Warner Lambert in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc., a pharmaceutical and biotechnology company, for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University. Dr. Wierenga is a member of the boards of directors of Onyx Pharmaceuticals, Inc. and Cytokinetics, Inc., which are publicly-traded biopharmaceutical companies.

Jackie Cossmon

Basic Compensation

Options Compensation

Search Stocks